1. Home
  2. SCLXW vs REGCP Comparison

SCLXW vs REGCP Comparison

Compare SCLXW & REGCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCLXW
  • REGCP
  • Stock Information
  • Founded
  • SCLXW N/A
  • REGCP N/A
  • Country
  • SCLXW United States
  • REGCP United States
  • Employees
  • SCLXW 113
  • REGCP 497
  • Industry
  • SCLXW Biotechnology: Pharmaceutical Preparations
  • REGCP
  • Sector
  • SCLXW Health Care
  • REGCP
  • Exchange
  • SCLXW Nasdaq
  • REGCP Nasdaq
  • Market Cap
  • SCLXW N/A
  • REGCP N/A
  • IPO Year
  • SCLXW 2021
  • REGCP N/A
  • Fundamental
  • Price
  • SCLXW $0.21
  • REGCP $23.50
  • Analyst Decision
  • SCLXW
  • REGCP
  • Analyst Count
  • SCLXW 0
  • REGCP 0
  • Target Price
  • SCLXW N/A
  • REGCP N/A
  • AVG Volume (30 Days)
  • SCLXW N/A
  • REGCP N/A
  • Earning Date
  • SCLXW N/A
  • REGCP N/A
  • Dividend Yield
  • SCLXW N/A
  • REGCP N/A
  • EPS Growth
  • SCLXW N/A
  • REGCP N/A
  • EPS
  • SCLXW N/A
  • REGCP N/A
  • Revenue
  • SCLXW N/A
  • REGCP N/A
  • Revenue This Year
  • SCLXW N/A
  • REGCP N/A
  • Revenue Next Year
  • SCLXW N/A
  • REGCP N/A
  • P/E Ratio
  • SCLXW N/A
  • REGCP N/A
  • Revenue Growth
  • SCLXW N/A
  • REGCP N/A
  • 52 Week Low
  • SCLXW N/A
  • REGCP N/A
  • 52 Week High
  • SCLXW N/A
  • REGCP N/A
  • Technical
  • Relative Strength Index (RSI)
  • SCLXW N/A
  • REGCP 32.39
  • Support Level
  • SCLXW N/A
  • REGCP $23.19
  • Resistance Level
  • SCLXW N/A
  • REGCP $24.39
  • Average True Range (ATR)
  • SCLXW 0.00
  • REGCP 0.25
  • MACD
  • SCLXW 0.00
  • REGCP -0.08
  • Stochastic Oscillator
  • SCLXW 0.00
  • REGCP 20.10

About SCLXW Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

About REGCP Regency Centers Corporation

Regency Centers is one of the largest shopping center-focused retail REITs. The company's portfolio includes an interest in 483 properties, which includes over 57 million square feet of retail space following the completion of the Urstadt Biddle acquisition in August 2023. The portfolio is geographically diversified with 22 regional offices and no single market representing more than 12% of total company net operating income. Regency's retail portfolio is primarily composed of grocery-anchored centers, with 80% of properties featuring a grocery anchor and grocery stores representing 20% of annual base rent.

Share on Social Networks: